The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice

Area of Science:

• Renal medicine
• Pharmacology
• Inflammation research

Background:

• Acute kidney injury (AKI) is a significant clinical challenge with high morbidity and mortality.
• Sphingolipid metabolism plays a crucial role in regulating inflammation and cell survival in AKI pathogenesis.
• Opaganib is an experimental drug designed to modulate sphingolipid metabolism and reduce inflammatory cytokine production.

Purpose of the Study:

• To evaluate the efficacy of opaganib in preclinical models of AKI.
• To investigate the role of sphingolipid metabolism in renal inflammatory damage.
• To determine the potential of opaganib as a therapeutic agent for AKI.

Main Methods:

• Murine models of AKI were established, including renal ischemia-reperfusion (IR) injury (moderate and severe) and lipopolysaccharide (LPS)-induced sepsis.
• Animals were treated orally with opaganib.
• Renal damage was assessed using biochemical assays (creatinine, blood urea nitrogen) and histological analysis of kidney tissue, including granulocyte infiltration.

Main Results:

• Opaganib treatment significantly reduced creatinine and blood urea nitrogen levels in moderate IR models.
• In severe IR models, opaganib decreased these markers and completely prevented mortality.
• Opaganib administration blunted inflammatory cytokine elevations in response to LPS, indicating anti-inflammatory effects.

Conclusions:

• Sphingolipid metabolism is a key mediator of renal inflammatory damage in AKI.
• Opaganib effectively suppresses renal inflammatory damage and mortality in preclinical AKI models.
• Opaganib's established clinical testing in other diseases warrants further investigation in surgical or septic patients at risk for AKI.